Apart from being a mouthful to say, Pramipexole Dihydrochloride is an FDA approved dopamine agonist. We’ve promoted it, as pramipexole, for use in research projects and have had it available for quite a while at gurupeptides.com. Because the substance is FDA approved, there are already some medications out to market using pramipexole dihydrochloride as the primary ingredient. That doesn’t mean you can’t use it in new laboratory research projects. At a relatively low price point, there is a very little risk involved to you.
Most frequently marketed in the prescription medications Mirapex and Mirapex ER, pramipexole is used to treat individuals suffering from Parkinson’s disease and/or restless legs syndrome. Being that pramipexole is a dopamine agonist, it activates dopamine receptors and Mirapex leverages that quality to instill temporary tranquility in people suffering from tremors. The body gets satisfied, the severe movements lessen or even stop. Since there isn’t a cure to Parkinson’s disease, the effects are temporary, but it can make the difference between a patient being able to drink a cup of coffee or not.
Fewer than 5% of patients that use the medicinal form of pramipexole experience side effects. That said, there are a large variety of side effects that can take place as a result of pramipexole supplementation. Considered to be the most common are nausea, drowsiness, and headache. None of them are too serious and most patients prescribed Mirapex decide that they’d rather live with the occasional side effect than the alternative.
There are more serious side effects, unfortunately. Much more rare than the aforementioned common risks, some people can struggle with digestive problems that lead to vomiting, weight gain, or constipation. In some really unfortunate cases, individuals have reported impotence and complete loss of sexual interest.
Knowing how effective pramipexole is when it comes to treatment for diseases like Parkinson’s, it is only normal to speculate that perhaps pramipexole dihydrochloride may be leveraged to find a cure. Studies are being conducted regularly with the one common goal in mind of eradicating Parkinson’s disease for good.
In 2012, Fatai Kunle Salawu explored the possibility that extended-release pramipexole could limit the effect of Parkinson’s disease if prescribed on the onset. Long term treatment of these slow-release medications would help maintain elevated levels of pramipexole dihydrochloride in the patient’s system, hopefully limiting or completely preventing the typical symptoms associated with Parkinson’s disease. Salawu’s findings concluded that “future therapies must combine symptomatic and disease-modifying agents” like pramipexole to beat the disease.
By 2017, alternate methods of the same idea were being explored. Inhalation for near immediate delivery to the brain could help patients see the relief and results that they’re looking for at a faster rate. Although this isn’t a cure, this would make the treatment nearly immediate and give instantaneous relief, similar to an inhaler for somebody with asthma.
Perhaps there will never be a cure developed. Perhaps pramipexole dihydrochloride isn’t the key to curing Parkinson’s or restless leg syndrome. Recent research proves that we’re close though. The future is bright.
Fatai Kunle Salawu. “Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole.” Patient Prefer Adherence., U.S. National Library of Medicine, 16 Jan. 2012, www.ncbi.nlm.nih.gov/pubmed/29247729.
Raj, R, et al. “Pramipexole Dihydrochloride Loaded Chitosan Nanoparticles for Nose to Brain Delivery: Development, Characterization and in Vivo Anti-Parkinson Activity.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, 1 Apr. 2018, www.ncbi.nlm.nih.gov/pubmed/29247729.